Daily FNArena News - FYI

Pitt Street Research initiates coverage of China-based eLearning SaaS company, Retech Technology.

The New Criterion’s Tim Boreham notes massive legal settlements in the US have highlighted the scourge of opioid abuse, but Australian producer Palla Pharma is confident the drug class will remain the world’s foremost pain medication.

Pitt Street Research has revised its valuation range for MyFiziq.

Peter Switzer of the Switzer Super Report suggests gold’s run is over and its time to back the stock market.

Pitt Street Research has initiated coverage of Sydney-based Energy Technologies, an emerging cable and wire player.

Pitt Street Research explains why Imagion Biosystems shares look undervalued.

Peter Switzer of the Switzer Super Report applies the “Buffett test” to the value of Link Administration.

Pitt Street Research finds vindication in BlackWall’s intention to spin off the Wotso flexible workspace business.

Pitt Street Research sees plenty of potential ahead for science-based neutraceutical products producer Abundant Produce.

Pitt Street Research interviewed Bob Proulx, CEO Imagion Biosystems